Redefining how injectable medicine is experienced
EFX MedTech develops patented single-use micro-injector and facial positioning systems that enable safe, precise at-home administration of botulinum toxin and other biologics.
​
Founded in Western Australia by anaesthetist Dr Emily Fergie, the company merges medical insight with engineering innovation to redefine how injectable drugs are prepared, delivered, and experienced outside clinical settings.
​
EFX’s proprietary delivery approach combines size-specific facial positioning masks with a dual-chamber auto-injector platform that automatically reconstitutes and delivers micro-doses through integrated injector cells - ensuring clinical-grade accuracy, fixed dosing, and low contamination risk.
The technology is protected by multiple granted and pending patents spanning facial sizing, device architecture, and anatomically-targeted microlitre dosing.
Our Mission
To make precision injectable medicine accessible, consistent, and effortless.
We engineer intelligent delivery systems that merge safety, accuracy, and simplicity to empower patients to self-administer advanced treatments with the same confidence and precision once possible only under clinical supervision.
The Future Is Ours
Where We're Going
EFX Medical Technologies is building a new paradigm for drug delivery - one where injectable therapies are portable, personalised, and integrated into daily life. ​
​
Our R&D roadmap extends beyond aesthetics to therapeutic applications, from neuromodulator treatments for migraine and hyperhidrosis to other biologic drugs. By advancing regulatory pathways, scaling manufacturing, and partnering with pharmaceutical innovators, we aim to lead the global shift toward next-generation, at-home precision injectables - setting the standard for safety, efficacy, and patient empowerment.
​
EFX is pursuing a commercialisation strategy anchored in licensing and co-development partnerships with pharmaceutical and aesthetic drug manufacturers.